Southern Colorado Therapy Care, Inc. Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 6230 Waco Mish Road, Colorado City, CO 81019 Phone: 719-240-3128 |
Mrs. Melanie J. Palcic, M.A.-CCC, SLP Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 6230 Waco Mish Road, Colorado City, CO 81019 Phone: 719-251-2398 Fax: 719-676-2351 |
Anne Esther Maroney, MS, CCC/SLP Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 5148 Little Raven Drive, Colorado City, CO 81019 Phone: 719-252-2032 |
News Archive
Oraya Therapeutics, Inc. announced today that they have been awarded a $215,000 Small Business Technology Transfer Grant from the National Institutes of Health to investigate how Oraya Therapy, a low voltage stereotactic radiotherapy, and gold nanoparticles can further enhance the treatment of wet age-related macular degeneration (Wet AMD).
Ever since the Accreditation Council for Graduate Medical Educations (ACGME) and its Resident Review Committees instituted limitations on duty-hours for residents, in 2003, there has been an ongoing debate about the benefits and costs of the changes imposed on patient care and the education of residents.
Albany Molecular Research (AMRI) reported that its Holywell, Wales-based wholly owned subsidiary AMRI U.K., has been awarded a seven-year contract for the development and manufacture of an undisclosed active ingredient under clinical evaluation.
In a study to be presented today at the Society for Maternal-Fetal Medicine's (SMFM) annual meeting, The Pregnancy Meeting -, in San Francisco, researchers will present findings that show that when women administer their own patient-controlled epidural analgesia (PCEA) instead of getting a continuous epidural infusion (CEI) they used less analgesic, but reported similar levels of satisfaction.
Medicago Inc., a biotechnology company focused on developing highly effective and competitive vaccines based on proprietary manufacturing technologies and Virus-Like Particles, today announced that it has entered into a research collaboration agreement for the development of a non-influenza vaccine candidate with a top 10 global pharmaceutical company.
› Verified 4 days ago